CD8A and neoplasm: We previously demonstrated that targeted deletion of Cxcr2 in myeloid cells or systemic treatment with the CXCR1/CXCR2 antagonist SX-682 conferred anti-tumor immunity via reduction of MDSC infiltration into the TME and enhanced CD8 + T cell activation [9].